Intellia Therapeutics: A Worst-Case Risk Becomes A Tragic Reality (Downgrade)

Intellia Therapeutics pauses Nex-z gene-editing trial after participant death. Click here for my updated look at NTLA stock ...

Boomerang Ventures Makes Seed-Stage Investment in SynchNeuro to Advance Brain-Based Non-Invasive Glucose Monitoring Technology

SynchNeuro is a Portfolio Company of Boomerang Ventures INDIANAPOLIS, IN / ACCESS Newswire / November 12, 2025 / Boomerang Ventures adds SynchNeuro, Inc. to its portfolio of seed-stage investments, ...